GSTP1 determines cis-platinum cytotoxicity in gastric adenocarcinoma MGC803 cells: Regulation by promoter methylation and extracellular regulated kinase signaling

Anti-Cancer Drugs

Volumn 20, Issue 3, 2009, Pages 208-214

  Zhang, Ye ^a   Qu, Xiujuan ^a   Jing, Wei ^a   Hu, Xuejun ^b   Yang, Xianghong ^c   Hou, Kezuo ^a   Teng, Yuee ^a   Zhang, Jingdong ^a   Liu, Yunpeng ^a,c  

^a Department of Medical Oncology ^*  (China)

^b First Hospital   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin; DNA methylation; Extracellular regulated kinase; Gastric cancer; Glutathione S transferases

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 AZA 2' DEOXYCYTIDINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DNA METHYLATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; AZACITIDINE; CELL LINE, TUMOR; CISPLATIN; CPG ISLANDS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MAP KINASE SIGNALING SYSTEM; METABOLIC DETOXICATION, DRUG; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 61749084094     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328322fbaa     Document Type: Article

References (37)

1. Yamaoka Y, Kalo M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 2008; 47:1077-1083.
2. Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance. Br J Cancer 2008; 98:1803-1809.
3. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98:1398-1402.
4. Valentini A, Pucci D, Crispini A, Federici G, Bernardini S. Acridine Orange based platinum (II) complexes inducing cytotoxicity and cell cycle perturbation in spite of GSTP1 up-regulation. Chem Biol Interact 2006; 161:241-250.
5. Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 2007; 15:1049-1053.
6. Frankmoelle WP, Medina JC, Shan B, Narbut MR, Beckmann H. Glutathione S-transferase metabolism of the antineoplastic pentafluorophenyl-sulfonamide in tissue culture and mice. Drug Metab Dispos 2000; 28:951-958.
7. Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 2004; 12:631-637.
8. Wang X, Wang L, Yuan Y. Expression of pi glutathione S-transferase in intestinal metaplasia and its relationship with Helicobacter pylori infection. Zhonghua Yi Xue Za Zhi 2002; 82:1033-1036.
9. Zhang Y, Sun LR Chen W, Bai XL, Liu J, Wang XG, et al. A molecular epidemiological study on the relationship between the polymorphism of GSTP1 and susceptibility to gastric cancer in northern Chinese. Yi Chuan 2007; 29:293-300.
10. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S- transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 2008; 26:344-351.
11. Chen WY, Mao WM, Zhao L, Chen GP, Shu Y, Shen YF, et al. Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance. Zhonghua Zhong Liu Za Zhi 2005; 27:738-740.
12. Eguchi-Nakajima T, Yamada Y. Predictive markers for platinum-based chemotherapy. Gan To Kagaku Ryoho 2008; 35:185-189.
13. Doǧru-Abbasoǧlu S, Mutlu-Türkoǧlu U, Türkoǧlu S, Erbil Y, Barbaros U, Uysal M, et al. Glutathione S-transferase-pi in malignant tissues and plasma of human colorectal and gastric cancers. J Cancer Res Clin Oncol 2002; 128:91-95.
14. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008; 71:161-167.
15. Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 2006; 100:169-176.
16. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, Dang LH. Glutathione S-transferase pi 1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 2005; 65:9485-9494.
17. Kim SG, Lee SJ. PI3 K, RSK, and mTOR signal networks for the GST gene regulation. Toxicol Sci 2007; 96:206-213.
18. Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, Chapelier A, et al. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 2007; 120:1579-1590.
19. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251:1-16.
20. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005; 65:8423-8432.
21. Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol 2007; 104:338-344.
22. Villedieu M, Deslandes E, Duval M, Héron JF, Gauduchon P, Poulain L. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment. Gynecol Oncol 2006; 101:507-519.
23. Esteller M, Corn PG, Urenal JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1999; 58:4515-4518.
24. Qu X, Liu Y, Ma Y, Zhang Y, Li Y, Hou K. Up-regulation of the Cbl family of ubiquitin ligases is involved in ATRA and bufalin-induced cell adhesion but not cell differentiation. Biochem Biophys Res Commun 2008; 367: 183-189.
25. Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006; 10:345-352.
26. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 2005; 35:714-719.
27. Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL, Tangrea JA. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008; 179:508-512.
28. Kollermann J, Kempkensteffen C, Helpap B, Schrader M, Krause H, Muller M, et al. Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer. BMC Urol 2006; 6:15.
29. Eilers T, Machtens S, Tezval H, Blaue C, Lichtinghagen R, Hagemann J, et al. Prospective diagnostic efficiency of biopsy washing DNA GSTP1 island hypermethylation for detection of adenocarcinoma of the prostate. Prostate 2007; 67:757-763.
30. Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect 2007; 31:59-63.
31. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, et al. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer 2007; 97:1260-1265.
32. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Lee PH, et al. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett 2005; 221:135-143.
33. Arai T, Miyoshi Y, Kim SJ, Akazawa K, Maruyama N, Taguchi T, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008; 34: 734-738.
34. Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch 2007; 450:637-642.
35. Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer 2006; 107:1042-1049.
36. Ishii T, Fujishiro M, Masuda M, Teramoto S, Matsuse T. A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. Cancer Lett 2004; 212:211-223.
37. Lee SM, Lee CT, Kim YW, Han SK, Shim YS, Yoo CG. Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung cancer cells. Cancer Lett 2006; 242:231-238.